Recently, we identified recurrent gene fusions involving the 59 untranslated region of the androgen-regulated gene TMPRSS2 and the ETS (E26 transformation-specific) family genes ERG, ETV1 or ETV4 in most prostate cancers 1,2 . Whereas TMPRSS2-ERG fusions are predominant, fewer TMPRSS2-ETV1 cases have been identified than expected on the basis of the frequency of high (outlier) expression of ETV1 (refs 3-13). Here we explore the mechanism of ETV1 outlier expression in human prostate tumours and prostate cancer cell lines. We identified previously unknown 59 fusion partners in prostate tumours with ETV1 outlier expression, including untranslated regions from a prostatespecific androgen-induced gene (SLC45A3) and an endogenous retroviral element (HERV-K_22q11.23), a prostate-specific androgen-repressed gene (C15orf21), and a strongly expressed housekeeping gene (HNRPA2B1). To study aberrant activation of ETV1, we identified two prostate cancer cell lines, LNCaP and MDA-PCa 2B, that had ETV1 outlier expression. Through distinct mechanisms, the entire ETV1 locus (7p21) is rearranged to a 1.5-megabase prostate-specific region at 14q13.3-14q21.1 in both LNCaP cells (cryptic insertion) and MDA-PCa 2B cells (balanced translocation). Because the common factor of these rearrangements is aberrant ETV1 overexpression, we recapitulated this event in vitro and in vivo, demonstrating that ETV1 overexpression in benign prostate cells and in the mouse prostate confers neoplastic phenotypes. Identification of distinct classes of ETS gene rearrangements demonstrates that dormant oncogenes can be activated in prostate cancer by juxtaposition to tissue-specific or ubiquitously active genomic loci. Subversion of active genomic regulatory elements may serve as a more generalized mechanism for carcinoma development. Furthermore, the identification of androgenrepressed and insensitive 59 fusion partners may have implications for the anti-androgen treatment of advanced prostate cancer.
Recently, we identified recurrent gene fusions involving the 59 untranslated region of the androgen-regulated gene TMPRSS2 and the ETS (E26 transformation-specific) family genes ERG, ETV1 or ETV4 in most prostate cancers 1, 2 . Whereas TMPRSS2-ERG fusions are predominant, fewer TMPRSS2-ETV1 cases have been identified than expected on the basis of the frequency of high (outlier) expression of ETV1 (refs 3-13). Here we explore the mechanism of ETV1 outlier expression in human prostate tumours and prostate cancer cell lines. We identified previously unknown 59 fusion partners in prostate tumours with ETV1 outlier expression, including untranslated regions from a prostatespecific androgen-induced gene (SLC45A3) and an endogenous retroviral element (HERV-K_22q11.23), a prostate-specific androgen-repressed gene (C15orf21), and a strongly expressed housekeeping gene (HNRPA2B1). To study aberrant activation of ETV1, we identified two prostate cancer cell lines, LNCaP and MDA-PCa 2B, that had ETV1 outlier expression. Through distinct mechanisms, the entire ETV1 locus (7p21) is rearranged to a 1.5-megabase prostate-specific region at 14q13.3-14q21.1 in both LNCaP cells (cryptic insertion) and MDA-PCa 2B cells (balanced translocation). Because the common factor of these rearrangements is aberrant ETV1 overexpression, we recapitulated this event in vitro and in vivo, demonstrating that ETV1 overexpression in benign prostate cells and in the mouse prostate confers neoplastic phenotypes. Identification of distinct classes of ETS gene rearrangements demonstrates that dormant oncogenes can be activated in prostate cancer by juxtaposition to tissue-specific or ubiquitously active genomic loci. Subversion of active genomic regulatory elements may serve as a more generalized mechanism for carcinoma development. Furthermore, the identification of androgenrepressed and insensitive 59 fusion partners may have implications for the anti-androgen treatment of advanced prostate cancer.
Recurrent chromosomal rearrangements have been causally implicated in haematological and mesenchymal malignancies; although predicted to occur in common epithelial carcinomas, they have not been well characterized 14, 15 . Using a bioinformatics strategy to nominate genes showing high (outlier) expression in a subset of cancers, we identified fusions of the 59-untranslated region of TMPRSS2 (21q22) to ERG (21q22), ETV1 (7p21) or ETV4 (17q21) in cases that overexpressed the respective ETS family member 1, 2 . TMPRSS2 had previously been characterized as androgen-regulated 16 , and its androgen-responsive regulatory elements drive ETS family member outlier expression 1, 17 . Thus, fusions between TMPRSS2 and ETS family members are functionally similar to haematological malignancy rearrangements in which tissue-specific promoter or enhancer elements of one gene are juxtaposed to proto-oncogenes 15, 18 . Multiple studies have confirmed the presence of TMPRSS2-ERG fusions in 36-78% of prostate cancers from prostate-specificantigen-screened surgical cohorts (Supplementary Table 1 ). Approximately 90% of samples with ERG outlier expression harbour TMPRSS2-ERG fusions 1, 19 , confirming this as the predominant mechanism driving ERG overexpression. In contrast, although microarray studies show ETV1 outlier expression in 6-16% of prostate cancer samples, only 2 of 205 (1.0%) samples analysed harboured TMPRSS2-ETV1 fusions (Supplementary Table 1) .
Here we addressed this discrepancy between ETV1 outlier and TMPRSS2-ETV1 frequencies. By quantitative PCR (Q-PCR) across 2 cohorts, 26 and 3 of 54 localized prostate cancer samples showed ERG (48%) and ETV1 (5.5%) outlier expression, respectively ( Supplementary Fig. 1 ). Additionally, two hormone-refractory metastatic prostate cancer samples, MET26 (our TMPRSS2-ETV1 index case 1 ) and MET23, showed ETV1 outlier expression. However, other than MET26, no samples expressed TMPRSS2-ETV1 fusion transcripts.
To characterize the ETV1 transcript in outlier cases, we performed 59-RNA-ligase-mediated rapid amplification of complementary DNA ends (RLM-RACE). Instead of 59 exons from TMPRSS2, the other four samples contained unique 59 sequences (Fig. 1a) . In PCa_ETV1_1, exons 1-4 of ETV1 were replaced with two exons from 22q11.23 that had homology to human endogenous retrovirus family K (referred to as HERV-K_22q11.23). In PCa_ETV1_2, exon 1 of ETV1 was replaced with exon 1 of HNRPA2B1 (7p15), whereas in PCa_ETV1_3, exons 1-4 of ETV1 were replaced with a 59-extended exon 1 of SLC45A3 (1q32). In MET23, exons 1-5 of ETV1 were replaced with exons 1-2 from C15orf21 (15q21) (Fig. 1a) . We confirmed these fusion transcripts by Q-PCR and genomic fusions by fluorescent in situ hybridization (FISH; Supplementary Figs 2 and 3) . Additional information about the 59 partners and the FISH results is described in Supplementary Discussion.
HERV-K_22q11.23-ETV1, SLC45A3-ETV1 and C15orf21-ETV1 fusions contain no predicted translated sequences from the 59 partner, and HNRPA2B1 would only contribute two residues to a HNRPA2B1-ETV1 fusion protein. Because their regulatory elements probably drive aberrant ETV1 expression, we characterized the tissue specificity and androgen regulation of these 59 partners by microarray or massively parallel signature sequencing (MPSS, as described in the Methods). Similar to TMPRSS2, SLC45A3 showed marked overexpression in prostate cancer (median is 2.45 standard deviations above the median value per array) compared to other tumour types (median 5 0.33, P 5 2.4 3 10 -7 ) in a large DNA microarray study. C15orf21 showed similar overexpression in prostate cancer (P 5 3. 4 3 10 -6 ). In contrast, HNRPA2B1 showed high expression in prostate and other tumour types (median 5 2.36 versus 2.41, P . 0.05) (Fig. 1b) . By MPSS, HERV-K_22q11.23 was shown to be highly expressed in normal prostate (94 transcripts per million) compared to the 31 other normal tissues (median 5 9 transcripts per million; Fig. 1b) . By Q-PCR, endogenous expression of SLC45A3 (21.6-fold, P 5 6.5 3 10 -4 ) and HERV-K_22q11.23 (7.8-fold, P 5 2.4 3 10 -4 ) in the LNCaP prostate cancer cell line was shown to be greatly increased by the synthetic androgen R1881, similar to TMPRSS2 (14.8-fold, P 5 9.95 3 10 -7 ). Conversely, the expression of C15orf21 was significantly decreased (1.9-fold, P 5 0.0012) and the expression of HNRPA2B1 was not affected by R1881 stimulation (1.17-fold, P 5 0.29) (Fig. 1c) .
We next sought to identify cell-line models of ETV1 outlier expression. Previously, we reported that the LNCaP cell line markedly overexpressed ETV1, however RLM-RACE revealed expression of only the wild-type transcript 1 . We proposed that LNCaP may harbour a previously unknown rearrangement affecting the expression of ETV1, and used a split-probe FISH strategy to look for gross rearrangements (Fig. 2) . On LNCaP metaphase spreads, this assay revealed two pairs of co-localizing signals at the ETV1 locus (7p) and two split signals in which the 59 signals remained on 7p whereas the 39 probes (overlapping the ETV1 locus) were inserted into another chromosome (Fig. 2b) . As described in the Supplementary Discussion and Supplementary Figs 4-8, we identified this rearrangement as a cryptic insertion of a minimal region around ETV1 into an intronic sequence from the MIPOL1 locus at 14q13.3-14q21.1 in the LNCaP cell line (Fig. 2d) . C15orf21-ETV1 By screening additional prostate cancer cell lines for ETV1 overexpression, we identified ETV1 outlier expression in MDA-PCa 2B ( Supplementary Fig. 9 ). A previous analysis of MDA-PCa 2B demonstrated the presence of a balanced t(7;14)(p21;q21) 20 translocation corresponding to the locations of the ETV1 and MIPOL1 loci. We demonstrate that MDA-PCa 2B also harbour a rearrangement involving ETV1, because the ETV1 locus translocates to the d14 (Fig. 2c) . The 1.5-Mb 14q13.3-14q21.1 region is the partner of this balanced translocation, because the telomeric 14q13.3-14q21.1 probe localizes to the d7 ( Supplementary Fig. 7 ).
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The existence of mechanistically distinct rearrangements resulting in the localization of ETV1 to 14q13.3-14q21.1 ( Fig. 2e ) in prostate cancer cell lines with ETV1 outlier expression suggests that elements in this region mediate the aberrant expression of ETV1. By characterizing the tissue specificity and androgen regulation of the four contiguous genes at the 14q13.3-14q21.1 breakpoint ( Fig. 2d ; SLC25A21, MIPOL1, FOXA1 and TTC6) as well as that of ETV1 in LNCaP and its androgen-insensitive derivative C4-2B, we demonstrate that this region is both prostate-specific and coordinately regulated by androgen (Supplementary Figs 10-12 and Supplementary Discussion).
The 59 partners do not contribute a coding sequence to the ETV1 transcript, therefore the common result of the different ETV1 rearrangements in clinical samples and prostate cancer cell lines is aberrant overexpression of truncated ETV1. We recapitulated this event in vitro and in vivo to determine the role of aberrant ETS family member expression in prostate cancer. We designed adenoviral and lentiviral constructs to overexpress ETV1, as expressed in our index TMPRSS2-ETV1 fusion-positive case MET26 ( Supplementary Fig.  13a ). In RWPE and PrEC cells, ETV1 overexpression had no detectable effect on proliferation ( Supplementary Fig. 13b, c) . ETV1 overexpression had no effect on the percentage of RWPE cells in the S phase of the cell cycle ( Supplementary Fig. 13d ) and was not sufficient for transformation ( Supplementary Fig. 13e ). However, ETV1 overexpression markedly increased invasion in a modified basement membrane invasion assay in RWPE (3.4-fold, P 5 0.0005) (Fig. 3a) and PrEC (6.3-fold, P 5 0.0006) (Supplementary Fig. 14a ). Additionally, ETV1 knockdown in LNCaP using either short interfering (si)RNA or short hairpin (sh)RNA inhibited invasion ( Fig. 3b and Supplementary Fig. 14b-d) , consistent with previous work 21 . To investigate the transcriptional programme regulated by ETV1, we profiled stable RWPE-ETV1 cells and analysed the expression signatures using the Oncomine Concepts Map (OCM, http://www. oncomine.org). The OCM is a resource to look for associations between more than 20,000 biologically related gene sets by disproportionate overlap 10, 22 . As shown in Fig. 3c , OCM analysis identified a network of molecular concepts related to cell invasion that were enriched in our ETV1-overexpressed signature, consistent with the phenotypic effects described above. Specific examples are described in Supplementary Discussion.
We next determined the effects of ETV1 overexpression in vivo. We generated transgenic mice expressing a Flag-tagged, truncated version of ETV1 under the control of the modified probasin promoter (ARR2Pb-ETV1) ( Supplementary Fig. 13a ), which drives strong transgene expression exclusively in the prostate under androgen regulation 23 . This transgene is functionally analogous to the androgen-induced gene fusions of ETV1 we identified in human prostate cancer. By 12-14 weeks of age, 6 of 8 (75%) ARR2Pb-ETV1 mice developed mouse prostatic intraepithelial neoplasia (mPIN) (Fig. 4 and Supplementary Table 5 ). Consistent with the definition of mPIN 24 , we observed focal proliferative lesions contained within normal glands in the prostates of ARR2Pb-ETV1 mice (Fig. 4a-d) ; these lesions exhibited nuclear atypia, including stratification, hyperchromasia and macronucleoli. mPIN was observed in all three prostatic lobes (anterior, ventral and dorsolateral) of ARR2Pb-ETV1 mice, most commonly in the ventral lobe (7 of 11, 63.6%) (Supplementary Table 5 ). By immunohistochemistry in ARR2Pb-ETV1 mice, we observed strong ETV1-Flag expression exclusively in mPIN foci and not in benign glands (data not shown). Although we have not observed progression to invasive carcinoma in ARR2Pb-ETV1 mice, we have only characterized 4 mice older than 19 weeks of age, 3 of which (75%) also had mPIN (Supplementary Including fusions between TMPRSS2 and ETS family members, we have now identified five classes of ETS rearrangements in prostate cancer ( Supplementary Fig. 15 ). Identification of untranslated regions from the prostate-specific androgen-induced gene TMPRSS2 has provided a mechanism for aberrant ETS family member expression. Thus, fusions between TMPRSS2 and ETS family members (class I) represent the predominant class of ETS rearrangements in prostate cancer. Rearrangements involving fusions with untranslated regions from other prostate-specific androgen-induced 59 partner genes (class IIa) or endogenous retroviral elements (class IIb) are probably functionally similar to TMPRSS2-ETS rearrangements. Similar to 59 partners in class I and II ETS rearrangements, C15orf21 is markedly overexpressed in prostate cancer; however, because C15orf21 is repressed by androgen, this represents a previously unknown class of rearrangements (class III) involving prostate-specific androgen-repressed 59 partners.
In contrast, HNRPA2B1, which encodes a member of the ubiquitously expressed heteronuclear ribonuclear proteins, did not show prostate-specific expression or androgen responsiveness. Thus, HNRPA2B1-ETV1 represents a previously unknown class of ETS rearrangements (class IV), in which non-tissue-specific promoter elements drive ETS expression. Whereas class I-III ETS rearrangements are functionally analogous to IGH-MYC rearrangements in B-cell malignancies, HNRPA2B1-ETV1 is more analogous to inv(3)(q21q26) and t(3;3)(q21;q26) in acute myeloid leukaemia, which are thought to place EVI1 (ecotropic viral integration site 1) under the control of enhancer elements of the constitutively expressed RPN1 gene 25, 26 . By screening prostate cancer cell lines that have ETV1 outlier expression, we identified rearrangements in LNCaP and MDA-PCa 2B that result in the localization of ETV1 to 14q13.3-14q21.1. Because this aberration is recurrent in prostate cancer cell lines, we propose that characterizing additional prostate cancer cases with ETV1 outlier expression will identify clinical specimens with similar rearrangements (class V), in which the entire ETS family gene is rearranged to prostate-specific regions. The identification of distinct Fig. 13a ). Mice were killed at 12-43 weeks and mPIN was observed in 75% of ARR2Pb-ETV1 mice (Supplementary Table 5 classes of 59 fusion partners has implications for the detection of gene fusions in prostate cancer and may be important for management, particularly with regard to the effects of androgen ablation on the expression of the different ETS rearrangement classes (Supplementary Fig. 16 ), as described in Supplementary Discussion. Multiple classes of gene rearrangements in prostate cancer suggest a generalized role for chromosomal rearrangements in common epithelial cancers. For example, tissue-specific promoter elements may be fused to oncogenes in other hormone-driven cancers, such as breast cancer. Additionally, whereas prostate-specific fusions would not provide a growth advantage and be selected for in other epithelial cancers, fusions involving strong promoters of ubiquitously expressed genes, such as HNRPA2B1, could result in the aberrant expression of oncogenes across tumour types. This study supports a role for chromosomal rearrangements in common epithelial tumour development through a variety of mechanisms, similar to haematological malignancies.
METHODS SUMMARY
Q-PCR, RLM-RACE for ETV1 fusions, androgen stimulation of LNCaP cells and interphase FISH were performed essentially as described 1,2 using indicated oligonucleotide primers (Supplementary Table 2 ) and bacterial artificial chromosome (BAC) probes (Supplementary Table 3 ). Tissue-specific expression of 59 fusion partners was determined using the International Genomics Consortium's expO data set accessed in the Oncomine database 27 and the Lynx Therapeutics MPSS data set (GSE1747). Expression profiling was performed using Agilent Whole Human Genome Oligo Microarrays. Adenoviruses and lentiviruses expressing ETV1 were generated by the University of Michigan Vector Core. Transgenic ARR2Pb-ETV1 mice were generated by the University of Michigan Transgenic Animal Model Core.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
METHODS
Samples and cell lines. Prostate tissues were from the radical prostatectomy series at the University of Michigan and from the Rapid Autopsy Program 29 , both of which are part of University of Michigan Prostate Cancer Specialized Program of Research Excellence Tissue Core. All samples were collected with informed consent of the patients and previous institutional review board approval.
The benign immortalized prostate cell line RWPE and the prostate cancer cell lines LNCaP, Du145 NCI-H660 and PC3 were obtained from the American Type Culture Collection. Primary benign prostatic epithelial cells (PrEC) were obtained from Cambrex Bio Science. The prostate cancer cell lines C4-2B, LAPC4 and MDA-PCa 2B were provided by E. Keller. The prostate cancer cell line 22-RV1 was provided by J. Macoska. VCaP was derived from a vertebral metastasis from a patient with hormone-refractory metastatic prostate cancer 30 . For androgen stimulation experiments, LNCaP cells were grown in charcoalstripped serum containing media for 24 h, before treatment for 24 h with 1% ethanol or 1 nM of methyltrienolone (R1881, NEN Life Science Products) dissolved in ethanol. For all samples, total RNA was isolated with Trizol (Invitrogen) according to the manufacturer's instructions. Quantitative PCR. Q-PCR was performed using Power SYBR Green Mastermix (Applied Biosystems) on an Applied Biosystems 7300 Real Time PCR system as described 1, 2 . All oligonucleotide primers were synthesized by Integrated DNA Technologies and are listed in Supplementary Table 2 . HMBS and GAPDH 31 , and PSA 32 primer sequences were as described. Androgen stimulation reactions were performed in quadruplicate, siRNA knockdown reactions were performed in triplicate and all other reactions were performed in duplicate. RNA-ligase-mediated rapid amplification of cDNA ends. RLM-RACE was performed using the GeneRacer RLM-RACE kit (Invitrogen), according to the manufacturer's instructions as described 1, 2 . To obtain the 59 end of ETV1, firststrand cDNA was amplified with Platinum Taq High Fidelity (Invitrogen) using the GeneRacer 59 primer and ETV1_exon4-5-r. For amplification from MET23, ETV1_exon7-r was used with the GeneRacer 59 primer. Products were cloned and sequenced bidirectionally as described 1, 2 . RLM-RACE cDNA was not used for other assays. Fluorescence in situ hybridization. Interphase FISH on formalin-fixed paraffin-embedded tissue sections was performed as described 2 . A minimum of 50 nuclei per assay were evaluated. For metaphase FISH, spreads of LNCaP and MDA-PCa 2B were prepared using standard cytogenetic techniques. Slides were pre-treated in 2 3 SSC for 2 min, 70% ethanol for 2 min and 100% ethanol for 2 min, and then air-dried. Slides and probes were co-denatured at 75 uC for 2 min, and hybridized overnight at 37 uC. Post-hybridization was in 0.5 3 SSC at 42 uC for 5 min, followed by 3 washes in 1 3 phosphate buffered saline with 0.1% Tween-20 (PBST). Fluorescent detection was performed using anti-digoxigenin conjugated to fluorescein (Roche Applied Science) and streptavidin conjugated to Alexa Fluor 594 (Invitrogen). Slides were counterstained and mounted in ProLong Gold Antifade Reagent with DAPI (Invitrogen). Slides were examined using a Zeiss Axio Imager Z1 fluorescence microscope (Zeiss) and imaged with a CCD camera using ISIS software (Metasystems). At least five metaphases were assessed, and reported aberrations were observed in all interpretable spreads. BACs (listed in Supplementary Table 3) were obtained from the BACPAC Resource Center, and probes were prepared as described 2 . Pre-labelled chromosome 7 centromere and 7p telomeric probes were obtained from Vysis. The integrity and correct localization of all probes were verified by hybridization to metaphase spreads of normal peripheral lymphocytes. Tissue-specific expression. To determine the tissue-specific expression of 59 fusion partners and genes at 14q13-q21, we interrogated the International Genomics Consortium's expO data set (http://expo.intgen.org/expo/public/ downloaddata.jsp), consisting of expression profiles from 630 tumours of 29 distinct types, using the Oncomine database (http://www.oncomine.org) 27 . To interrogate the expression of HERV-K_22q11.23, which is not monitored by commercial array platforms, we queried the Lynx Therapeutics normal tissue MPSS data set (GSE1747) with the MPSS tag 'GATCTTTGTGACCTACT', which unambiguously identifies HERV-K_22q11.23, as described 33 . Descriptions of tumour types from the expO data set and the normal tissue types from the MPSS data set are provided in Supplementary Table 4 . Expression profiling. Expression profiling of LNCaP, C4-2B, RWPE-ETV1 and RWPE-GUS cells was performed using the Agilent Whole Human Genome Oligo Microarray. Total RNA isolated using Trizol was purified using the Qiagen RNAeasy Micro kit. One microgram of total RNA was converted to cRNA and labelled according to the manufacturer's protocol (Agilent). Hybridizations were performed for 16 h at 65 uC, and arrays were scanned using an Agilent DNA microarray scanner. Images were analysed and data were extracted using Agilent Feature Extraction Software 9.1.3.1, with linear and lowess normalization performed for each array. For the LNCaP and C4-2B hybridizations, the reference for each cell line was pooled benign prostate total RNA (Clontech). A dye flip for each cell line was also performed. Features were ranked by average expression (log ratio) in the two LNCaP arrays divided by the average expression in the two C4-2B arrays after correction for the dye flip. For RWPE cells, four hybridizations were performed (duplicate RWPE-ETV1/RWPE-GUS and RWPE-GUS/RWPE-ETV1 hybridizations). Over-and under-expressed signatures were generated by filtering to include only features with significant differential expression (P-value logratio , 0.01) in all four hybridizations and twofold average over-or under-expression (log ratio) after correction for the dye flip. Over-and under-expressed RWPE-ETV1/RWPE-GUS signatures were loaded into the Molecular Concepts Map 22 , resulting in concepts containing 527 and 558 unique genes, respectively. Each signature was tested against all contained concepts in the Molecular Concepts Map for association using Fisher's exact test as described 10, 22 . Southern hybridization. Genomic DNA (10 mg) from LNCaP, VCaP, pooled normal human male DNA (Promega) and normal placental DNA (Promega) was digested with EcoRI or PstI (New England Biologicals) overnight. Fragments were resolved on a 0.8% agarose gel at 40 V overnight, transferred to Hybond NX nylon membrane, pre-hybridized, hybridized with probe and washed according to standard protocols. A series of 22 probes spanning the region of chromosome 7 implicated by FISH (between RP11-313C20 and RP11-703A4) were generated by PCR amplification with Platinum Taq High Fidelity on pooled normal human male genomic DNA (Supplementary Table 2 and Supplementary Fig. 5 ). Twenty-five nanograms of each probe was labelled with dCTP-32 P and used for hybridization. Inverse PCR. To identify the ETV1 breakpoint in LNCaP cells, we used an inverse PCR strategy based on the rearrangement identified by Southern blotting (probe A, Supplementary Table 2) as described previously 34 and shown in Supplementary Fig. 6 . Primers A1, A2 and A3, which are reverse complemented from the wild-type sequence and are divergent to primers B1, B2 and B3, were used for inverse PCR on PstI-digested and religated (to promote intramolecular ligation) LNCaP genomic DNA template. Nested PCRs were performed in the following order of primer combinations: A1-B1, A2-B2 and A3-B3. The Expand 20 kbplus PCR system (Roche) was used for amplifying the fusion product according to the manufacturer's suggestions. The enriched 3-kb band observed in nested PCRs was cloned into pCR8/GW/TOPO (Invitrogen), miniprep DNA was screened for inserts, and positive clones were sequenced (University of Michigan DNA Sequencing Core). The ETV1 insertion was confirmed by PCR with Platinum Taq High Fidelity using primers from chromosomes 7 and 14 (Supplementary Table 2 ). In vitro overexpression of ETV1. cDNA of ETV1, as present in the TMPRSS2-ETV1 fusion to the reported stop codon of ETV1 (269-1521, NM_004956.3), was amplified by RT-PCR from MET26 (ref. 1) and TOPO cloned into the Gateway entry vector pCR8/GW/TOPO (Invitrogen), yielding pCR8-ETV1. To generate adenoviral and lentiviral constructs, pCR8-ETV1 and a control entry clone (pENTR-GUS) were recombined with pAD/CMV/V5 (Invitrogen) and pLenti6/CMV/V5 (Invitrogen), respectively, using LR Clonase II (Invitrogen). Control pAD/CMV/LACZ clones were obtained from Invitrogen. Adenoviruses and lentiviruses were generated by the University of Michigan Vector Core. The benign immortalized prostate cell line RWPE was infected with lentiviruses expressing ETV1 or GUS, and stable clones were generated by selection with blasticidin (Inivtrogen). Benign PrEC were infected with adenoviruses expressing ETV1 or LACZ, because stable lines could not be generated in primary PrEC cells. Cell counts were estimated by treating cells with trypsin, and analysis was performed by a Coulter counter at the indicated time points in triplicate. For invasion assays, PrEC-ETV1 and PrEC-LACZ (48 h after infection) or stable RWPE-ETV1 and RWPE-GUS cells were used. Representative results from three separate experiments are shown in Fig. 3a and Supplementary Fig. 14 . ETV1 knockdown. For siRNA knockdown of ETV1 in LNCaP cells, the individual siRNAs composing the Dharmacon SMARTpool against ETV1 (MU-003801-01) were tested for ETV1 knockdown by Q-PCR, and the most effective single siRNA (D-003801-05) was used for further experiments. siCONTROL non-targeting siRNA number 1 (D-001210-01) or siRNA against ETV1 was transfected into LNCaP cells using Oligofectamine (Invitrogen). After 24 h we performed a second identical transfection, and cells were harvested 24 h later for RNA isolation and invasion assays as described below. For shRNA knockdown of ETV1 in LNCaP cells, the microRNA-adapted shRNA construct against ETV1 from the pMS2 retroviral vector (V2HS_61929, Open Biosystems) was cloned into an empty pGIPZ lentiviral vector (RHS4349, Open Biosystems) according to the manufacturer's protocol. pGIPZ lentiviruses with microRNA-adapted shRNAs against ETV1 or a non-silencing control (RHS4346) were generated by the University of Michigan Vector Core. LNCaP cells were infected with lentiviruses, and 48 h later cells were used for invasion assays as described below. Representative results from six independent experiments are reported.
